Comparison of AzurRx BioPharma Inc. (AZRX) and BioSpecifics Technologies Corp. (NASDAQ:BSTC)

As Biotechnology companies, AzurRx BioPharma Inc. (NASDAQ:AZRX) and BioSpecifics Technologies Corp. (NASDAQ:BSTC) are our subject to contrast. And more specifically their profitability, analyst recommendations, risk, institutional ownership, dividends, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
AzurRx BioPharma Inc. N/A 0.00 13.53M -0.88 0.00
BioSpecifics Technologies Corp. 32.96M 14.76 20.05M 2.40 29.63

Table 1 highlights AzurRx BioPharma Inc. and BioSpecifics Technologies Corp.’s top-line revenue, earnings per share (EPS) and valuation.


Table 2 shows the return on assets, return on equity and net margins of the two firms.

Net Margins Return on Equity Return on Assets
AzurRx BioPharma Inc. 0.00% -301.4% -154.5%
BioSpecifics Technologies Corp. 60.83% 21.8% 20.7%


3.9 and 3.9 are the respective Current Ratio and a Quick Ratio of AzurRx BioPharma Inc. Its rival BioSpecifics Technologies Corp.’s Current and Quick Ratios are 48.4 and 48.4 respectively. BioSpecifics Technologies Corp. has a better chance of clearing its pay short and long-term debts than AzurRx BioPharma Inc.

Analyst Recommendations

The table delivered features the ratings and recommendations for AzurRx BioPharma Inc. and BioSpecifics Technologies Corp.

Sell Ratings Hold Ratings Buy Ratings Rating Score
AzurRx BioPharma Inc. 0 0 0 0.00
BioSpecifics Technologies Corp. 0 0 1 3.00

On the other hand, BioSpecifics Technologies Corp.’s potential upside is 27.28% and its consensus price target is $85.

Insider and Institutional Ownership

AzurRx BioPharma Inc. and BioSpecifics Technologies Corp. has shares owned by institutional investors as follows: 16.3% and 61.3%. Insiders owned roughly 5.4% of AzurRx BioPharma Inc.’s shares. Insiders Competitively, owned 2.5% of BioSpecifics Technologies Corp. shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
AzurRx BioPharma Inc. -1.44% -2.97% 3.54% -18.65% -21.46% 69.42%
BioSpecifics Technologies Corp. 2.61% 9.45% 20.32% 40.89% 78.69% 17.36%

For the past year AzurRx BioPharma Inc. has stronger performance than BioSpecifics Technologies Corp.


BioSpecifics Technologies Corp. beats AzurRx BioPharma Inc. on 10 of the 11 factors.

AzurRx BioPharma, Inc., a clinical development stage biopharmaceutical company, engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of two therapeutic proteins under development, including MS1819, an autologous yeast recombinant lipase, which is in Phase IIa trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, a recombinant b-lactamase combination of bacterial origin for the prevention of hospital-acquired infections, as well as antibiotic-associated diarrhea. The company was incorporated in 2014 and is headquartered in Brooklyn, New York.

BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for multiple indications in the United States. The company offers injectable collagenase for the treatment of DupuytrenÂ’s contracture and PeyronieÂ’s disease under the XIAFLEX brand in Canada and Australia, as well as under XIAPEX brand name in Europe. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, and plantar fibromatosis, as well as for the treatment of human lipoma and uterine fibroids. The company is also involved in the development of other clinical indications for which collagenase injection has been tested, such as keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs, and as an adjunct to vitrectomy. It has a development and license agreement with Endo Global Ventures. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Lynbrook, New York.